7 assets in Thoracic Cancer

Therapeutic assets addressing Thoracic Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Thoracic Cancer	M.D. Anderson Cancer Center	P2	B (62)
Catequentinib Thoracic Cancer	JIANYANG WANG	P2	CCC (53)
Pedmark® Sts Thoracic Cancer	University of Arizona	P1/2	CC (45)
Rmc-6236 Thoracic Cancer	Tango Therapeutics, Inc.	P1/2	CC (45)
Rmc-9805 Thoracic Cancer	Tango Therapeutics, Inc.	P1/2	CC (45)
tng462 Thoracic Cancer	Tango Therapeutics, Inc.	P1/2	CC (45)
Cabozantinib Thoracic Cancer	M.D. Anderson Cancer Center	P1	CC (43)